/
APGE
$134.45-$0.10 (-0.07%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$10.2B
76M shares
52-week range
$35.39 – $134.88
100% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$113.22
Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
www.apogeetherapeutics.com- Employees
- 261
- IPO / List date
- Jul 14, 2023
- HQ
- SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds APGE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 41,100 | $1.8M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2008-01-08 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded APGE yet.
